These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8534589)

  • 21. Receptor scintigraphy with 111In-pentetreotide for endocrine gastroenteropancreatic tumors.
    Joseph K; Stapp J; Reinecke J; Skamel HJ; Höffken H; Neuhaus C; Lenze H; Trautmann ME; Arnold R
    Horm Metab Res Suppl; 1993; 27():28-35. PubMed ID: 8330869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy.
    Lamberts SW; Hofland LJ; van Koetsveld PM; Reubi JC; Bruining HA; Bakker WH; Krenning EP
    J Clin Endocrinol Metab; 1990 Sep; 71(3):566-74. PubMed ID: 2168430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
    Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
    Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of somatostatin analogues for the detection and treatment of gastrinoma in a dog.
    Altschul M; Simpson KW; Dykes NL; Mauldin EA; Reubi JC; Cummings JF
    J Small Anim Pract; 1997 Jul; 38(7):286-91. PubMed ID: 9239629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors.
    Eisenwiener KP; Prata MI; Buschmann I; Zhang HW; Santos AC; Wenger S; Reubi JC; Mäcke HR
    Bioconjug Chem; 2002; 13(3):530-41. PubMed ID: 12009943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of endocrine gastroenteropancreatic tumors with somatostatin analogues.
    Fehmann HC; Wulbrand U; Arnold R
    Recent Results Cancer Res; 2000; 153():15-22. PubMed ID: 10626286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.
    Shojamanesh H; Gibril F; Louie A; Ojeaburu JV; Bashir S; Abou-Saif A; Jensen RT
    Cancer; 2002 Jan; 94(2):331-43. PubMed ID: 11900219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined octreotide and peptide receptor radionuclide therapy ((90)Y-DOTA-TATE) in case of malignant insulinoma.
    Fischbach J; Gut P; Matysiak-Grześ M; Klimowicz A; Gryczyńska M; Waśko R; Ruchała M
    Neuro Endocrinol Lett; 2012; 33(3):273-8. PubMed ID: 22635083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
    Ur E; Bomanji J; Mather SJ; Britton KE; Wass JA; Grossman AB; Besser GM
    Clin Endocrinol (Oxf); 1993 May; 38(5):501-6. PubMed ID: 8101146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Somatostatin-receptor imaging in the localization of endocrine tumors.
    Lamberts SW; Bakker WH; Reubi JC; Krenning EP
    N Engl J Med; 1990 Nov; 323(18):1246-9. PubMed ID: 2170840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging.
    Shi W; Johnston CF; Buchanan KD; Ferguson WR; Laird JD; Crothers JG; McIlrath EM
    QJM; 1998 Apr; 91(4):295-301. PubMed ID: 9666953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide.
    Breeman WA; Hofland LJ; van der Pluijm M; van Koetsveld PM; de Jong M; Setyono-Han B; Bakker WH; Kwekkeboom DJ; Visser TJ; Lamberts SW
    Eur J Nucl Med; 1994 Apr; 21(4):328-35. PubMed ID: 7911760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SPECT imaging with 111In-octreotide for the localization of pancreatic insulinoma.
    Signore A; Procaccini E; Chianelli M; Salerno G; Iozzo P; Annovazzi A; Leonetti F; Tamburrano G; Ronga G
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):111-2. PubMed ID: 9002765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
    Nilsson O; Kölby L; Wängberg B; Wigander A; Billig H; William-Olsson L; Fjälling M; Forssell-Aronsson E; Ahlman H
    Br J Cancer; 1998 Feb; 77(4):632-7. PubMed ID: 9484822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incremental diagnostic value and impact on patient management of somatostatin receptor scintigraphy with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors.
    Usmani S; Khan HA; Abdulla M; Ahmed N; abu Huda F; Marafi F; al Kandari F; al Mohannadi S; al Nafisi N
    Med Princ Pract; 2011; 20(4):356-61. PubMed ID: 21576997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complete clinical remission and disappearance of liver metastases after treatment with somatostatin analogue in a 40-year-old woman with a malignant insulinoma positive for somatostatin receptors type 2.
    Romeo S; Milione M; Gatti A; Fallarino M; Corleto V; Morano S; Baroni MG
    Horm Res; 2006; 65(3):120-5. PubMed ID: 16479142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A new diagnostic method: somatostatin receptor scintigraphy of neuroendocrine tumors].
    Westlin JE; Janson ET; Ahlström H; Ohrvall U; Arnberg H; Nilsson S; Akerström G; Oberg K
    Lakartidningen; 1992 Dec; 89(50):4377-9. PubMed ID: 1469974
    [No Abstract]   [Full Text] [Related]  

  • 38. [111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment.
    Janson ET; Westlin JE; Eriksson B; Ahlström H; Nilsson S; Oberg K
    Eur J Endocrinol; 1994 Dec; 131(6):577-81. PubMed ID: 7804439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
    Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
    J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metastatic Insulinoma Controlled by Targeted Radionuclide Therapy With 177Lu-DOTATATE in a Patient With Solitary Kidney and MEN-1 Syndrome.
    Novruzov F; Mehmetbeyli L; Aliyev JA; Abbasov B; Mehdi E
    Clin Nucl Med; 2019 Jun; 44(6):e415-e417. PubMed ID: 30789400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.